CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: **Submission of Integrated Filing (Financial) for the Half Year ended September 30, 2026**

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulation 10(1A) of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024, NSE Circular No. NSE/CML/2025/20 dated April 02, 2025, read with NSE/CML/2025/02 dated January 02, 2025 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, we are submitting herewith the Integrated Filing (Unaudited Standalone Financial Result and Unaudited Consolidated Financial Result) of the Company for the half year ended September 30, 2026.

This is for your information and record.

Thanking You,
Yours Truly

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Bhawna Bisht
Company Secretary and Compliance Officer
Membership No. A70843

Encl as above



Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

General information about company	
Scrip code*	000000
NSE Symbol*	ANONDITA
MSEI Symbol*	NOTLISTED
ISIN*	INE0VTV01012
Name of company	ANONDITA MEDICARE LIMITED
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2026
Date of end of financial year	31-03-2027
Date of board meeting when results were approved	14-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	--
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Half Yearly
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	MANUFACTURE OF CONDOMS
Start date and time of board meeting	14-11-2026 16:00
End date and time of board meeting	14-11-2026 18:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	No
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	No
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	

(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		24-09-2026
Indicate Company website link for updated RPT policy of the Company		https://anonditamedicare.com/AMLPolicy.php
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		Yes
No. of times funds raised during the quarter		3
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	The Company has not defaulted in payment of Loan and Debt securities or its interest

Financial Results – Other than Bank				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
	Date of start of reporting period	01-04-2026	01-04-2026	
	Date of end of reporting period	30-09-2026	30-09-2026	
	Whether results are audited or unaudited	Unaudited	Unaudited	
	Nature of report standalone or consolidated	Standalone	Standalone	
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**			
1	**Revenue From Operations**			
	Revenue from operations	5786.31	5786.31	
	Other income	90.21	90.21	
	Total Income	**5876.52**	**5876.52**	
2	**Expenses**			
(a)	Cost of materials consumed	2774.37	2774.37	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-542.12	-542.12	
(d)	Employee benefit expense	426.87	426.87	
(e)	Finance costs	231.37	231.37	
(f)	Depreciation and amortisation expense	141.79	141.79	
(g)	**Other Expenses**			
1	Selling and Distribution Expenses	97.87	97.87	
2	Administrative Expenses	635.28	635.28	
	Total other expenses	**733.15**	**733.15**	
	Total expenses	**3765.43**	**3765.43**	
3	**Profit before exceptional and extraordinary items and tax**	**2111.09**	**2111.09**	
4	Exceptional items	0	0	
5	**Profit before extraordinary items and tax**	2111.09	2111.09	
6	Extraordinary items	0	0	
7	**Profit before tax**	2111.09	2111.09	
8	**Tax Expense**			
	Current tax	486.9	486.9	
	Deferred tax	44.94	44.94	
	Total tax expenses	531.84	531.84	

9	**Net Profit Loss for the period from continuing operations**	1579.25	1579.25	
10	Profit (loss) from discontinuing operations before tax	0	0	
11	Tax expense of discontinuing operations	0	0	
12	**Net profit (loss) from discontinuing operation after tax**	0	0	
13	**Profit (loss) for period before minority interest**	1579.25	1579.25	
14	Share of profit (loss) of associates			
15	Profit (loss) of minority interest			
16	**Net profit (Loss) for the period**	1579.25	1579.25	
17	**Details of equity share capital**			
	Paid-up equity share capital	1904.48	1904.48	
	Face value of equity share capital	10	10	
	Details of debt securities			
18	Reserves excluding revaluation reserve			
19	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	8.71	8.71	
	Diluted earnings (loss) per share from continuing and discontinued operations	8.71	8.71	
20	Debt equity ratio			Textual Information(1)
21	Debt service coverage ratio			Textual Information(2)
22	Interest service coverage ratio			Textual Information(3)
23	Disclosure of notes on financial results		Textual Information(4)	

Text Block	
Textual Information(1)	Out of the total amount of Rs.2,958.30 Lakhs, an amount of Rs.739.58 Lakhs, representing 25% of the Warrant Issue Price, has been received. The balance amount of Rs.2,218.73 Lakhs, representing the remaining 75%, shall be receivable upon exercise of the Warrants, in accordance with the applicable terms and conditions.
Textual Information(2)	
Textual Information(3)	
Textual Information(4)	

Statement of Asset and Liabilities		
	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Equity and liabilities	
1	**Shareholders' funds**	
	Share capital	1904.48
	Reserves and surplus	19930.17
	Money received against share warrants	739.58
	Total shareholders' funds	**22574.23**
2	Share application money pending allotment	0
3	Deferred government grants	0
4	Minority interest	
5	**Non-current liabilities**	
	Long-term borrowings	4248.49
	Deferred tax liabilities (net)	169.83
	Foreign currency monetary item translation difference liability account	0
	Other long-term liabilities	
1		
2		
3		
4		
5		
	Details of other long-term liabilities	
	Total of other long-term liabilities	
	Long-term provisions	26.66
	Total non-current liabilities	**4444.98**
6	**Current liabilities**	
	Short-term borrowings	2533.47
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	164.22
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1041.38
	Total Trade payable	**1205.6**

	Other current liabilities	
1	Advance from Customer	47.59
2	Statutory Liabilities	25.34
3	Expense Payable	141.23
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	**214.16**
	Short-term provisions	894.64
	Total current liabilities	**4847.87**
	Total equity and liabilities	**31867.08**
	Assets	
1	**Non-current assets**	
(i)	**Property, Plant and Equipment and Intangible assets**	
	Property, Plant and Equipment	5295.77
	Producing properties	
	Intangible assets	0
	Preproducing properties	
	Property, Plant and Equipment capital work-in-progress	7420.55
	Intangible assets under development or work-in-progress	
	Total Property, Plant and Equipment and Intangible assets	**12716.32**
(ii)	Non-current investments	351.58
(v)	Deferred tax assets (net)	0
(vi)	Foreign currency monetary item translation difference asset account	0
(vii)	Long-term loans and advances	317.06
	Other non-current assets	
1	Preliminary Expense	0.12
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	**0.12**
	Total non-current assets	**13385.08**
2	**Current assets**	
	Current investments	0
	Inventories	2043.75
	Trade receivables	4821.52

	Cash and cash equivalents	18.98
	Bank balance other than cash and cash equivalents	9126.77
	Short-term loans and advances	1790.4
	Other current assets	
1	Other Current Asset	680.58
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	**680.58**
	Total current assets	**18482**
	Total assets	**31867.08**
	Disclosure of notes on assets and liabilities	

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results			
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-09-2026	30-09-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
1	**Segment Revenue**		
	(net sale/income from each segment should be disclosed)		
	Total segment revenue		
	Less: Inter segment revenue		
	Revenue from operations		
2	**Segment Result**		
	Profit (+) / Loss (-) before tax and interest from each segment		
	Total Profit before tax		
	i. Finance cost		
	ii. Other unallocable expenditure net off unallocable income		
	Profit before tax		
3	**(Segment Asset - Segment Liabilities)**		
	Segment Asset		
	Total Segment Assets		
	Un-allocable Assets		
	Net Segment Assets		
4	**Segment Liabilities**		
	Segment Liabilities		
	Total Segment Liabilities		
	Un-allocable Liabilities		
	Net Segment Liabilities		

Cash flow statement - indirect		
	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
1	**Statement of cash flows**	
	Cash flows from used in operating activities	
	Profit before extraordinary items and tax	2111.09
2	**Adjustments for reconcile profit (loss)**	
	Adjustments to profit (loss)	
	Adjustments for finance costs	195.43
	Adjustments for depreciation and amortisation expense	141.79
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for share-based payments	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments to profit (loss)	**337.22**
3	**Adjustments for working capital**	
	Adjustments for decrease (increase) in inventories	-694.61
	Adjustments for decrease (increase) in trade receivables	-1022.72
	Adjustments for decrease (increase) in other current assets	-864.13
	Adjustments for increase (decrease) in trade payables	411.73
	Adjustments for increase (decrease) in other current liabilities	1585.99
	Adjustments for provisions	-47.03
	Total adjustments for working capital	**-630.77**
	Total adjustments for reconcile profit (loss)	**-293.55**
	Net cash flows from (used in) operations	**1817.54**
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	68.64
	Other inflows (outflows) of cash	0

	Net cash flows from (used in) operating activities before extraordinary items	**1748.9**
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) operating activities	**1748.9**
4	**Cash flows from used in investing activities**	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property plant and equipment	-4800.62
	Purchase of property plant and equipment	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Cash advances and loans made to other parties	142
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	35.93
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Proceeds from government grants	0
	Net cash flows from (used in) investing activities before extraordinary items	**-4906.69**
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) investing activities	**-4906.69**
5	**Cash flows from used in financing activities**	
	Proceeds from issuing shares	95.82
	Proceeds from issuing other equity instruments	739.58
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	1888.87
	Repayments of borrowings	0
	Dividends paid	0
	Interest paid	231.37

	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	8856.54
	Net cash flows from (used in) financing activities before extraordinary items	**11349.44**
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) financing activities	**11349.44**
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	**8191.65**
6	**Effect of exchange rate changes on cash and cash equivalents**	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	**8191.65**
	Cash and cash equivalents cash flow statement at beginning of period	954.1
	Cash and cash equivalents cash flow statement at end of period	**9145.75**

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th qu

															Additional disclosure c relates to loans, in entity/subsidiary. Thes	
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial incurred to make or g corporate deposits, investme	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedn
1	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Rent & Maintenance	400	Approved			99.12	0	0		
2	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	Subsidiary Company	Loan		2500	Approved			1298.18	571.89	713.9	Loan	
3	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	Subsidiary Company	Loan		2500	Approved			1182.95	0	0		
4	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	Subsidiary Company	Interest received		2500	Approved			26.77	0	0		
5	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	Subsidiary Company	Sale of goods or services		3500	Approved			510.56	332.47	617.05		
6	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare	ABXFA1571G	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Car Rent Service Received	150	Approved			88.5	0	0		
7	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products	AANCA1209M	ENTITY UNDER COMMON	Any other transaction	Corporate Guarantee	374	Approved			5.83	373.06	367.23		

			Private Limited		CONTROL PROMOTER											
8	Anondita Medicare Limited	ABACA3332M	Anupam Ghosh	AEQPG6875G	Promoter and Managing Director	Any other transaction	Personal Guarantee	400	Approved			6.18	400	393.82		
Total value of transaction during the reporting period												3218.09				

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Public Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	28-08-2025
Amount Raised	6949.85
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	No deviation or variation has been reported by the Monitoring Agency in the utilisation of IPO proceeds
Comments of the Audit Committee after review	The Audit Committee has reviewed the Monitoring Agency Report and noted that no deviation or variation has been reported in the utilisation of IPO proceeds
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have not observed any deviation or variation in the utilisation of IPO proceeds from the objects stated in the Prospectus

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Funding Working Capital Requirements	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of Rs. 278.41 Lacs out of Object 3 (ie General Corporate Purposes) towards funding the Companys working capital requirements including working capital loans and Cash Credit (CC) limits and with this reallocation the revised total allocation for working capital now stands at Rs. 3,778.41 Lacs Furthermore utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Companys expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of 100 crore for FY 2025–26, which has now been revised to approximately 145 crore.	3500	3778.41	3778.41	0	No deviation reported by the Monitoring Agency.
2	General Corporate Purpose (GCP)	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds allocated for Object 3 (Unidentified Acquisition and General Corporate Purposes) will to be utilized for GCP only now restricted to 25% of the total IPO proceeds. Any amount excess of GCP Limit will be transferred towards meeting the Companys working capital requirements. No unidentified acquisition will be undertaken using the IPO proceeds. Furthermore, the allocation of Rs. 278.41 Lacs from Object 3 to Object 2 for funding the Company's working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at Rs. 1,737.46 Lacs. Further while the utilization of these funds was initially projected over FY 2025–26 and FY 2026–27 and it was expected that the entire allocation was expected to be deployed within FY 2025–26 and yet the balance utilization will be made in this Financial year 2026-27	2015.87	1737.46	1737.46	0	
3	Capex	No variation in object of the issue except changes and or additions to vendors, as disclosed in the Prospectus	600	0	600	0	
4	Issue Related Expenses	NA	833.13	0	833.13	0	

Signatory Details	
Name of signatory	Anupam Ghosh
Designation of person	Managing Director
Place	Noida
Date	14-11-2026

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)	
Mode of Fund Raising	Rights Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	24-09-2026
Amount Raised	9102.58
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	No funds were utilised out of the proceeds raised through the Rights Issue up to September 30, 2026. Accordingly no deviation or variation has arisen during the reporting period.
Comments of the Audit Committee after review	The Audit Committee has reviewed the statement and noted that no funds were utilised out of the Rights Issue proceeds up to September 30 2026.
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have observed that no funds were utilised out of the Rights Issue proceeds up to September 30, 2026. Accordingly no deviation or variation in the utilisation of proceeds has arisen during the reporting period.

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Funding Working Capital Requirements	NO CHANGE	2574.96	0	0	0	
2	General Corporate Purpose (GCP)	NO CHANGE	981.46	0	0	0	
3	Capex	NO CHANGE	5000	0	0	0	
4	Issue Related Expenses	NO CHANGE	546.16	0	0	0	

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (3)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	08-07-2026
Amount Raised	2958.3
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	No deviation or variation has arisen during the reporting period
Comments of the Audit Committee after review	The Audit Committee has reviewed the statement and noted that no deviation or variation in the utilisation of proceeds has arisen during the reporting period
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have observed that no deviation or variation in the utilisation of proceeds has arisen during the reporting period

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Facility Establishment and Expansion Product Development for International Markets Digital Infrastructure Technology Platforms Brand Building Marketing & Promotional Activities	No	2958.3	0	739.28	0	* Out of the total size of Rs.2,958.30 Lakhs, Rs.739.58 Lakhs (25%of Warrant Issue Price) has been received, out of which Rs.739.28 Lakhs has been utilised and Rs.0.29 Lakhs remains unutilised as on September 30, 2026. The balance 75%, amounting to Rs.2,218.73 Lakhs, is receivable upon exercise of the Warrants. Accordingly, the total unutilised and receivable amount aggregates to Rs.2,219.02 Lakhs.

General information about company	
Scrip code*	000000
NSE Symbol*	ANONDITA
MSEI Symbol*	NOTLISTED
ISIN*	INE0VTV01012
Name of company	ANONDITA MEDICARE LIMITED
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2026
Date of end of financial year	31-03-2027
Date of board meeting when results were approved	14-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	03-11-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Half Yearly
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	MANUFACTURE OF CONDOMS
Start date and time of board meeting	14-11-2026 16:00
End date and time of board meeting	14-11-2026 18:00
Whether cash flow statement is applicable on company	Yes

Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Other than Bank				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
	Date of start of reporting period	01-04-2026	01-04-2026	
	Date of end of reporting period	30-09-2026	30-09-2026	
	Whether results are audited or unaudited	Unaudited	Unaudited	
	Nature of report standalone or consolidated	Consolidated	Consolidated	
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**			
1	**Revenue From Operations**			
	Revenue from operations	7354.17	7354.17	
	Other income	60.48	60.48	
	Total Income	**7414.65**	**7414.65**	
2	**Expenses**			
(a)	Cost of materials consumed	2775.47	2775.47	
(b)	Purchases of stock-in-trade	1295.26	1295.26	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1277.67	-1277.67	
(d)	Employee benefit expense	461.46	461.46	
(e)	Finance costs	242.28	242.28	
(f)	Depreciation and amortisation expense	142.15	142.15	
(g)	**Other Expenses**			
1	Selling and Distribution Expense	119.94	119.94	
2	Administrative Expense	710.39	710.39	

	Total other expenses	**830.33**	**830.33**
	Total expenses	**4469.28**	**4469.28**
3	**Profit before exceptional and extraordinary items and tax**	**2945.37**	**2945.37**
4	Exceptional items	0	0
5	**Profit before extraordinary items and tax**	2945.37	2945.37
6	Extraordinary items	0	0
7	**Profit before tax**	2945.37	2945.37
8	**Tax Expense**		
	Current tax	699.83	699.83
	Deferred tax	44.94	44.94
	Total tax expenses	744.77	744.77
9	**Net Profit Loss for the period from continuing operations**	2200.6	2200.6
10	Profit (loss) from discontinuing operations before tax	0	0
11	Tax expense of discontinuing operations	0	0
12	**Net profit (loss) from discontinuing operation after tax**	0	0
13	**Profit (loss) for period before minority interest**	2200.6	2200.6
14	Share of profit (loss) of associates	2130.83	2130.83
15	Profit (loss) of minority interest	69.78	69.78
16	**Net profit (Loss) for the period**	4401.21	4401.21
17	**Details of equity share capital**		
	Paid-up equity share capital	1904.48	1904.48
	Face value of equity share capital	10	10
	Details of debt securities		

18	Reserves excluding revaluation reserve			
19	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	11.76	11.76	
	Diluted earnings (loss) per share from continuing and discontinued operations	11.76	11.76	
20	Debt equity ratio			Textual Information(1)
21	Debt service coverage ratio			Textual Information(2)
22	Interest service coverage ratio			Textual Information(3)
23	Disclosure of notes on financial results		Textual Information(4)	

Text Block	
Textual Information(1)	
Textual Information(2)	
Textual Information(3)	
Textual Information(4)	

Statement of Asset and Liabilities

	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated
	Equity and liabilities	
1	**Shareholders' funds**	
	Share capital	1904.48
	Reserves and surplus	22102.43
	Money received against share warrants	739.58
	Total shareholders' funds	**24746.49**
2	Share application money pending allotment	0
3	Deferred government grants	0
4	Minority interest	272.99
5	**Non-current liabilities**	
	Long-term borrowings	4272.89
	Deferred tax liabilities (net)	169.83
	Foreign currency monetary item translation difference liability account	0
	Other long-term liabilities	
1		
2		
3		

4		
5		
	Details of other long-term liabilities	
	Total of other long-term liabilities	
	Long-term provisions	26.66
	Total non-current liabilities	**4469.38**
6	**Current liabilities**	
	Short-term borrowings	2787.95
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	164.22
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1066.17
	Total Trade payable	**1230.39**
	Other current liabilities	
1	Advance from Customer	68.38
2	Statutory Liabilities	30.72
3	Unearned Income	39.52
4	Expense payable	156.14
5		
	Details of other current liabilities	
	Total of other current liabilities	**294.76**
	Short-term provisions	1377.09
	Total current liabilities	**5690.19**
	Total equity and liabilities	**35179.05**
	Assets	
1	**Non-current assets**	

(i)	**Property, Plant and Equipment and Intangible assets**	
	Property, Plant and Equipment	5297.19
	Producing properties	0
	Intangible assets	19.18
	Preproducing properties	0
	Property, Plant and Equipment capital work-in-progress	7420.55
	Intangible assets under development or work-in-progress	
	Total Property, Plant and Equipment and Intangible assets	**12736.92**
(ii)	Non-current investments	331.4
(v)	Deferred tax assets (net)	0.25
(vi)	Foreign currency monetary item translation difference asset account	0
(vii)	Long-term loans and advances	317.06
	Other non-current assets	
1	Preliminary Expense	0.12
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	**0.12**
	Total non-current assets	**13385.75**
2	**Current assets**	
	Current investments	0
	Inventories	3516.88
	Trade receivables	6002.32

	Cash and cash equivalents	22.06
	Bank balance other than cash and cash equivalents	9128.93
	Short-term loans and advances	2356.89
	Other current assets	
1	Other Current Asset	766.22
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	**766.22**
	Total current assets	**21793.3**
	Total assets	**35179.05**
	Disclosure of notes on assets and liabilities	

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results			
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-09-2026	30-09-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated	Consolidated
1	**Segment Revenue**		
	(net sale/income from each segment should be disclosed)		
	Total segment revenue		
	Less: Inter segment revenue		
	Revenue from operations		
2	**Segment Result**		
	Profit (+) / Loss (-) before tax and interest from each segment		
	Total Profit before tax		
	i. Finance cost		
	ii. Other unallocable expenditure net off unallocable income		
	Profit before tax		
3	**(Segment Asset - Segment Liabilities)**		
	Segment Asset		
	Total Segment Assets		
	Un-allocable Assets		
	Net Segment Assets		
4	**Segment Liabilities**		

	Segment Liabilities		
	Total Segment Liabilities		
	Un-allocable Liabilities		
	Net Segment Liabilities		

Cash flow statement - indirect		
	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated
1	**Statement of cash flows**	
	Cash flows from used in operating activities	
	Profit before extraordinary items and tax	2945.37
2	**Adjustments for reconcile profit (loss)**	
	Adjustments to profit (loss)	
	Adjustments for finance costs	0
	Adjustments for depreciation and amortisation expense	142.15
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	236.08
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for share-based payments	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0.04
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments to profit (loss)	**378.27**
3	**Adjustments for working capital**	
	Adjustments for decrease (increase) in inventories	-1441.88

	Adjustments for decrease (increase) in trade receivables	-816.65
	Adjustments for decrease (increase) in other current assets	-1593.17
	Adjustments for increase (decrease) in trade payables	427.6
	Adjustments for increase (decrease) in other current liabilities	45.97
	Adjustments for provisions	-47.02
	Total adjustments for working capital	**-3425.15**
	Total adjustments for reconcile profit (loss)	**-3046.88**
	Net cash flows from (used in) operations	**-101.51**
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	68.63
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities before extraordinary items	**-170.14**
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) operating activities	**-170.14**
4	**Cash flows from used in investing activities**	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0

	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property plant and equipment	0
	Purchase of property plant and equipment	4800.63
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	6.2
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Proceeds from government grants	0
	Net cash flows from (used in) investing activities before extraordinary items	**-4794.43**
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) investing activities	**-4794.43**
5	**Cash flows from used in financing activities**	
	Proceeds from issuing shares	95.82
	Proceeds from issuing other equity instruments	739.58
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	3700.7
	Repayments of borrowings	0
	Dividends paid	0

	Interest paid	242.28
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	8856.54
	Net cash flows from (used in) financing activities before extraordinary items	**13150.36**
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) financing activities	**13150.36**
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	**8185.79**
6	**Effect of exchange rate changes on cash and cash equivalents**	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	**8185.79**
	Cash and cash equivalents cash flow statement at beginning of period	965.21
	Cash and cash equivalents cash flow statement at end of period	**9151**